Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients

Yuichi Takashi, Shu Wakino, Hitoshi Minakuchi, Masashi Ishizu, Akio Kuroda, Hisato Shima, Manabu Tashiro, Keiko Miya, Kazuyoshi Okada, Jun Minakuchi, Shu Kawashima, Munehide Matsuhisa, Toshio Matsumoto, Seiji Fukumoto

Research output: Contribution to journalArticle

Abstract

Fibroblast growth factor (FGF) 23 is a bone-derived hormone regulating serum inorganic phosphate (Pi) concentration. FGF23 is also involved in the development of chronic kidney disease (CKD)-mineral and bone disorder. Serum FGF23 concentration begins to increase early in the progression of CKD and can be remarkably high in hemodialysis patients with end-stage renal disease. It has been reported that high FGF23 concentration is a risk factor for cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. FGF23 was also shown to induce cardiac hypertrophy directly acting on cardiomyocytes. However, it is still controversial whether high FGF23 is causing cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. In the current study, we investigated whether FGF23 concentration is associated with cardiac dysfunction, atherosclerosis, infection or systemic inflammation in Japanese hemodialysis patients. We recruited 119 hemodialysis patients and examined the association between serum FGF23 concentration and several parameters concerning mineral metabolism, cardiac dysfunction, atherosclerosis, infection, and systemic inflammation. Serum FGF23 concentration was independently associated with serum calcium and Pi concentration (β = 0.276, p < 0.001; β = 0.689, p < 0.001). However, serum FGF23 concentration was not associated with parameters of cardiac dysfunction, atherosclerosis, infection, and systemic inflammation, either. Our results do not support the hypothesis that high FGF23 in dialysis patients is the cause of cardiac dysfunction, atherosclerosis, infection or systemic inflammation.

Original languageEnglish
JournalJournal of Bone and Mineral Metabolism
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Renal Dialysis
Atherosclerosis
Inflammation
Infection
Serum
Chronic Renal Insufficiency
Chronic Kidney Disease-Mineral and Bone Disorder
Cardiomegaly
Cardiac Myocytes
Chronic Kidney Failure
Minerals
Dialysis
Phosphates
Hormones
Calcium
Bone and Bones

Keywords

  • Atherosclerosis
  • Cardiac dysfunction
  • Fibroblast growth factor 23
  • Hemodialysis
  • Inorganic phosphate

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. / Takashi, Yuichi; Wakino, Shu; Minakuchi, Hitoshi; Ishizu, Masashi; Kuroda, Akio; Shima, Hisato; Tashiro, Manabu; Miya, Keiko; Okada, Kazuyoshi; Minakuchi, Jun; Kawashima, Shu; Matsuhisa, Munehide; Matsumoto, Toshio; Fukumoto, Seiji.

In: Journal of Bone and Mineral Metabolism, 01.01.2019.

Research output: Contribution to journalArticle

Takashi, Y, Wakino, S, Minakuchi, H, Ishizu, M, Kuroda, A, Shima, H, Tashiro, M, Miya, K, Okada, K, Minakuchi, J, Kawashima, S, Matsuhisa, M, Matsumoto, T & Fukumoto, S 2019, 'Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients', Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-019-01027-7
Takashi, Yuichi ; Wakino, Shu ; Minakuchi, Hitoshi ; Ishizu, Masashi ; Kuroda, Akio ; Shima, Hisato ; Tashiro, Manabu ; Miya, Keiko ; Okada, Kazuyoshi ; Minakuchi, Jun ; Kawashima, Shu ; Matsuhisa, Munehide ; Matsumoto, Toshio ; Fukumoto, Seiji. / Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. In: Journal of Bone and Mineral Metabolism. 2019.
@article{8d32a7508bda40be9ebc9861e787d281,
title = "Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients",
abstract = "Fibroblast growth factor (FGF) 23 is a bone-derived hormone regulating serum inorganic phosphate (Pi) concentration. FGF23 is also involved in the development of chronic kidney disease (CKD)-mineral and bone disorder. Serum FGF23 concentration begins to increase early in the progression of CKD and can be remarkably high in hemodialysis patients with end-stage renal disease. It has been reported that high FGF23 concentration is a risk factor for cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. FGF23 was also shown to induce cardiac hypertrophy directly acting on cardiomyocytes. However, it is still controversial whether high FGF23 is causing cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. In the current study, we investigated whether FGF23 concentration is associated with cardiac dysfunction, atherosclerosis, infection or systemic inflammation in Japanese hemodialysis patients. We recruited 119 hemodialysis patients and examined the association between serum FGF23 concentration and several parameters concerning mineral metabolism, cardiac dysfunction, atherosclerosis, infection, and systemic inflammation. Serum FGF23 concentration was independently associated with serum calcium and Pi concentration (β = 0.276, p < 0.001; β = 0.689, p < 0.001). However, serum FGF23 concentration was not associated with parameters of cardiac dysfunction, atherosclerosis, infection, and systemic inflammation, either. Our results do not support the hypothesis that high FGF23 in dialysis patients is the cause of cardiac dysfunction, atherosclerosis, infection or systemic inflammation.",
keywords = "Atherosclerosis, Cardiac dysfunction, Fibroblast growth factor 23, Hemodialysis, Inorganic phosphate",
author = "Yuichi Takashi and Shu Wakino and Hitoshi Minakuchi and Masashi Ishizu and Akio Kuroda and Hisato Shima and Manabu Tashiro and Keiko Miya and Kazuyoshi Okada and Jun Minakuchi and Shu Kawashima and Munehide Matsuhisa and Toshio Matsumoto and Seiji Fukumoto",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00774-019-01027-7",
language = "English",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients

AU - Takashi, Yuichi

AU - Wakino, Shu

AU - Minakuchi, Hitoshi

AU - Ishizu, Masashi

AU - Kuroda, Akio

AU - Shima, Hisato

AU - Tashiro, Manabu

AU - Miya, Keiko

AU - Okada, Kazuyoshi

AU - Minakuchi, Jun

AU - Kawashima, Shu

AU - Matsuhisa, Munehide

AU - Matsumoto, Toshio

AU - Fukumoto, Seiji

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Fibroblast growth factor (FGF) 23 is a bone-derived hormone regulating serum inorganic phosphate (Pi) concentration. FGF23 is also involved in the development of chronic kidney disease (CKD)-mineral and bone disorder. Serum FGF23 concentration begins to increase early in the progression of CKD and can be remarkably high in hemodialysis patients with end-stage renal disease. It has been reported that high FGF23 concentration is a risk factor for cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. FGF23 was also shown to induce cardiac hypertrophy directly acting on cardiomyocytes. However, it is still controversial whether high FGF23 is causing cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. In the current study, we investigated whether FGF23 concentration is associated with cardiac dysfunction, atherosclerosis, infection or systemic inflammation in Japanese hemodialysis patients. We recruited 119 hemodialysis patients and examined the association between serum FGF23 concentration and several parameters concerning mineral metabolism, cardiac dysfunction, atherosclerosis, infection, and systemic inflammation. Serum FGF23 concentration was independently associated with serum calcium and Pi concentration (β = 0.276, p < 0.001; β = 0.689, p < 0.001). However, serum FGF23 concentration was not associated with parameters of cardiac dysfunction, atherosclerosis, infection, and systemic inflammation, either. Our results do not support the hypothesis that high FGF23 in dialysis patients is the cause of cardiac dysfunction, atherosclerosis, infection or systemic inflammation.

AB - Fibroblast growth factor (FGF) 23 is a bone-derived hormone regulating serum inorganic phosphate (Pi) concentration. FGF23 is also involved in the development of chronic kidney disease (CKD)-mineral and bone disorder. Serum FGF23 concentration begins to increase early in the progression of CKD and can be remarkably high in hemodialysis patients with end-stage renal disease. It has been reported that high FGF23 concentration is a risk factor for cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. FGF23 was also shown to induce cardiac hypertrophy directly acting on cardiomyocytes. However, it is still controversial whether high FGF23 is causing cardiac dysfunction, atherosclerosis, infection or systemic inflammation in CKD patients. In the current study, we investigated whether FGF23 concentration is associated with cardiac dysfunction, atherosclerosis, infection or systemic inflammation in Japanese hemodialysis patients. We recruited 119 hemodialysis patients and examined the association between serum FGF23 concentration and several parameters concerning mineral metabolism, cardiac dysfunction, atherosclerosis, infection, and systemic inflammation. Serum FGF23 concentration was independently associated with serum calcium and Pi concentration (β = 0.276, p < 0.001; β = 0.689, p < 0.001). However, serum FGF23 concentration was not associated with parameters of cardiac dysfunction, atherosclerosis, infection, and systemic inflammation, either. Our results do not support the hypothesis that high FGF23 in dialysis patients is the cause of cardiac dysfunction, atherosclerosis, infection or systemic inflammation.

KW - Atherosclerosis

KW - Cardiac dysfunction

KW - Fibroblast growth factor 23

KW - Hemodialysis

KW - Inorganic phosphate

UR - http://www.scopus.com/inward/record.url?scp=85070757751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070757751&partnerID=8YFLogxK

U2 - 10.1007/s00774-019-01027-7

DO - 10.1007/s00774-019-01027-7

M3 - Article

AN - SCOPUS:85070757751

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

ER -